Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (239) 239
life sciences & biomedicine (228) 228
humans (200) 200
hematology (134) 134
male (115) 115
female (108) 108
middle aged (106) 106
multiple myeloma (105) 105
oncology (105) 105
aged (101) 101
adult (80) 80
multiple myeloma - drug therapy (59) 59
biological and medical sciences (57) 57
medical sciences (57) 57
aged, 80 and over (54) 54
immunoglobulinopathies (51) 51
life sciences (49) 49
prognosis (46) 46
abridged index medicus (45) 45
bortezomib (43) 43
multiple myeloma - pathology (41) 41
immunodeficiencies. immunoglobulinopathies (40) 40
immunopathology (40) 40
hematologic and hematopoietic diseases (37) 37
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (35) 35
multiple myeloma - mortality (35) 35
treatment outcome (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
cancer (32) 32
waldenstrom macroglobulinemia - drug therapy (29) 29
waldenstrom macroglobulinemia - pathology (27) 27
care and treatment (25) 25
multiple myeloma - genetics (24) 24
thalidomide - analogs & derivatives (24) 24
antineoplastic agents (23) 23
dexamethasone (23) 23
dexamethasone - administration & dosage (23) 23
animals (22) 22
follow-up studies (22) 22
retrospective studies (22) 22
survival analysis (22) 22
hematology, oncology and palliative medicine (21) 21
patients (21) 21
survival rate (21) 21
antineoplastic agents - therapeutic use (20) 20
pharmacology. drug treatments (20) 20
analysis (19) 19
medicin och hälsovetenskap (19) 19
waldenstrom macroglobulinemia - genetics (19) 19
bone marrow (18) 18
disease-free survival (18) 18
transplantation (18) 18
disease progression (17) 17
kaplan-meier estimate (17) 17
multiple myeloma - diagnosis (17) 17
recurrence (17) 17
boronic acids - administration & dosage (16) 16
cell line, tumor (16) 16
pyrazines - administration & dosage (16) 16
risk factors (16) 16
survival (16) 16
thalidomide - administration & dosage (16) 16
[sdv.can]life sciences [q-bio]/cancer (15) 15
chemical sciences (15) 15
immunology (15) 15
multiple myeloma - therapy (15) 15
myeloma (15) 15
stem cells (15) 15
mice (14) 14
organic chemistry (14) 14
prospective studies (14) 14
research (14) 14
sciences biologiques et medicales (14) 14
sciences medicales (14) 14
tumors (14) 14
chemotherapy (13) 13
multiple myeloma - metabolism (13) 13
remission induction (13) 13
waldenstrom macroglobulinemia - metabolism (13) 13
[sdv]life sciences [q-bio] (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
flow cytometry (12) 12
general & internal medicine (12) 12
hemic and lymphatic diseases (12) 12
relapse (12) 12
stem cell transplantation (12) 12
thalidomide (12) 12
thalidomide - adverse effects (12) 12
chromosome aberrations (11) 11
clinical trials (11) 11
hemopathies (11) 11
immunodéficits. immunoglobulinopathies (11) 11
immunopathologie (11) 11
lenalidomide (11) 11
medical research (11) 11
medicine, general & internal (11) 11
multiple myeloma - complications (11) 11
thalidomide - therapeutic use (11) 11
[chim.orga]chemical sciences/organic chemistry (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text New hope for relapsed and refractory multiple myeloma
by Leleu, Xavier
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1028 - 1029
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Female | Male | Drug Resistance, Neoplasm - drug effects | Relapse | Multiple myeloma | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A key to the quest?
by Leleu, Xavier
Blood, ISSN 0006-4971, 10/2014, Volume 124, Issue 14, pp. 2162 - 2163
Life Sciences & Biomedicine | Hematology | Science & Technology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Multiple Myeloma - drug therapy | Pyrazoles - administration & dosage | Humans | Female | Male | Thiophenes - administration & dosage | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
by Gagelmann, Nico and Eikema, Diderik-Jan and de Wreede, Liesbeth C and Rambaldi, Alessandro and Iacobelli, Simona and Koster, Linda and Caillot, Denis and Blaise, Didier and Rememyi, Peter and Bulabois, Claude-Eric and Passweg, Jakob and Leleu, Xavier and Zver, Samo and Kobbe, Guido and Ljungman, Per and Chevallier, Patrice and Ringhoffer, Mark and Martin, Murray and Salmenniemi, Urpu and Poire, Xavier and Lenhoff, Stig and Pioltelli, Pietro and Mordini, Nicola and Delforge, Michel and Garderet, Laurent and Schoenland, Stefan and Yakoub-Agha, Ibrahim and Kroeger, Nicolaus
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 01/2021, Volume 56, Issue 1, pp. 210 - 217
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Care and treatment | Diagnosis | Patient outcomes | Stem cells | Multiple myeloma | Confidence intervals | Autografts | Abnormalities | Stem cell transplantation | Survival | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
by Moreau, Philippe, Prof and Pylypenko, Halyna, MD and Grosicki, Sebastian, MD and Karamanesht, Ievgenii, MD and Leleu, Xavier, MD and Grishunina, Maria, MD and Rekhtman, Grigoriy, MD and Masliak, Zvenyslava, MD and Robak, Tadeusz, Prof and Shubina, Anna, MD and Arnulf, Bertrand, MD and Kropff, Martin, MD and Cavet, James, MBBS and Esseltine, Dixie-Lee, MD and Feng, Huaibao, PhD and Girgis, Suzette, PhD and van de Velde, Helgi, MD and Deraedt, William, MSc and Harousseau, Jean-Luc, Prof
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | South America | Recurrence | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Pyrazines - administration & dosage | Boronic Acids - adverse effects | Male | Multiple Myeloma - ethnology | Antineoplastic Agents - administration & dosage | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Aged, 80 and over | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Boronic Acids - administration & dosage | Blood Cells - drug effects | Multiple Myeloma - blood | Bortezomib | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Multiple Myeloma - pathology | Asia | Pyrazines - adverse effects | Aged | Infusions, Intravenous | Neoplasm Staging | Medical colleges | Medical research | Relapse | Multiple myeloma | Medicine, Experimental | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Thrombosis in Myeloma treated with IMiDs
by Leleu, Xavier
Thrombosis research, ISSN 0049-3848, 2012, Volume 130, Issue 1, pp. S63 - S65
Hematology, Oncology and Palliative Medicine | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Thromboembolism - chemically induced | Multiple Myeloma - mortality | Humans | Risk Factors | Multiple Myeloma - immunology | Treatment Outcome | Thromboembolism - mortality | Incidence | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Fibrinolytic Agents - therapeutic use | Immunologic Factors - adverse effects | Practice Guidelines as Topic | Thrombosis | Blood clot | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
by Attal, Michel and Lauwers-Cances, Valerie and Hulin, Cyrille and Leleu, Xavier and Caillot, Denis and Escoffre, Martine and Arnulf, Bertrand and Macro, Margaret and Belhadj, Karim and Garderet, Laurent and Roussel, Murielle and Payen, Catherine and Mathiot, Claire and Fermand, Jean P and Meuleman, Nathalie and Rollet, Sandrine and Maglio, Michelle E and Zeytoonjian, Andrea A and Weller, Edie A and Munshi, Nikhil and Anderson, Kenneth C and Richardson, Paul G and Facon, Thierry and Avet-Loiseau, Hervé and Harousseau, Jean-Luc and Moreau, Philippe and IFM 2009 Study
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
by Facon, Thierry and Kumar, Shaji and Plesner, Torben and Orlowski, Robert Z and Moreau, Philippe and Bahlis, Nizar and Basu, Supratik and Nahi, Hareth and Hulin, Cyrille and Quach, Hang and Goldschmidt, Hartmut and O’Dwyer, Michael and Perrot, Aurore and Venner, Christopher P and Weisel, Katja and Mace, Joseph R and Raje, Noopur and Attal, Michel and Tiab, Mourad and Macro, Margaret and Frenzel, Laurent and Leleu, Xavier and Ahmadi, Tahamtan and Chiu, Christopher and Wang, Jianping and Van Rampelbergh, Rian and Uhlar, Clarissa M and Kobos, Rachel and Qi, Ming and Usmani, Saad Z and MAIA Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 22, pp. 2104 - 2115
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Development and progression | Dosage and administration | Dexamethasone | Drug therapy | Multiple myeloma | Autografts | Pneumonia | Research & development--R&D | Minimal residual disease | Stem cell transplantation | Leukocytes | Evidence-based medicine | Chemotherapy | Lymphopenia | Risk assessment | Death | Neutropenia | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
by Dimopoulos, Meletios A and Dytfeld, Dominik and Grosicki, Sebastian and Moreau, Philippe and Takezako, Naoki and Hori, Mitsuo and Leleu, Xavier and LeBlanc, Richard and Suzuki, Kenshi and Raab, Marc S and Richardson, Paul G and Popa McKiver, Mihaela and Jou, Ying-Ming and Shelat, Suresh G and Robbins, Michael and Rafferty, Brian and San-Miguel, Jesús
The New England journal of medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 19, pp. 1811 - 1822
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Development and progression | Usage | Dexamethasone | Drug therapy | Multiple myeloma | Immunostimulation | Immunomodulation | Clinical trials | Patients | Survival | Evidence-based medicine | Proteasome inhibitors | Hyperglycemia | Chemotherapy | Medical prognosis | Response rates | Monoclonal antibodies | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
by Attal, Michel and Lauwers-Cances, Valerie and Marit, Gerald and Caillot, Denis and Moreau, Philippe and Facon, Thierry and Stoppa, Anne Marie and Hulin, Cyrille and Benboubker, Lofti and Garderet, Laurent and Decaux, Olivier and Leyvraz, Serge and Vekemans, Marie-Christiane and Voillat, Laurent and Michallet, Mauricette and Pegourie, Brigitte and Dumontet, Charles and Roussel, Murielle and Leleu, Xavier and Mathiot, Claire and Payen, Catherine and Avet-Loiseau, Hervé and Harousseau, Jean-Luc and IFM Investigators
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Bone marrow, stem cells transplantation. Graft versus host reaction | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Young Adult | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Chemotherapy | Consolidation | Transplants & implants | Clinical trials | Stem cell transplantation | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Abridged Index Medicus | Antineoplastic Agents | Life Sciences | Neoplasms, Second Primary | Thalidomide | Multiple Myeloma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
by Sagar Lonial and Ravi Vij and Jean-Luc Harousseau and Thierry Facon and Philippe Moreau and Amitabha Mazumder and Jonathan L. Kaufman and Xavier Leleu and L. Claire Tsao and Christopher Westland and Anil K. Singhal and Sundar Jagannath
Journal of clinical oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 16, pp. 1953 - 1959
Life Sciences & Biomedicine | Oncology | Science & Technology | Immunopathology | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Tumors | Recurrence | Dexamethasone - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thalidomide - administration & dosage | Disease Progression | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
by Dimopoulos, Meletios and Quach, Hang and Mateos, Maria-Victoria and Landgren, Ola and Leleu, Xavier and Siegel, David and Weisel, Katja and Yang, Hui and Klippel, Zandra and Zahlten-Kumeli, Anita and Usmani, Saad Z
The Lancet (British edition), ISSN 0140-6736, 07/2020, Volume 396, Issue 10245, pp. 186 - 197
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carfilzomib | Relapse | Care and treatment | Dexamethasone | Multiple myeloma | Diseases | Randomization | Bortezomib | Risk assessment | Antibodies | Bone marrow | Safety | Survival | Ejection fraction | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights